New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Topia Selected by Groupe SEB to Help Take Global Talent Mobility to the Next Level
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Pfizer (PFE) to Acquire Privately-Held Amplyx Pharmaceuticals
-
Pfizer Acquires Amplyx Pharmaceuticals
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Form SC 13D Reneo Pharmaceuticals, Filed by: New Enterprise Associates 15, L.P.
-
Blu Digital Group Secures Additional Investment to Extend Over-subscribed Series "A" Round
-
FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round
-
Lumos Pharma (LUMO) Announces Retirement of Carl Langren and Names Lori Lawley CFO in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
-
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
-
Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
-
Form SC 13D/A GENOCEA BIOSCIENCES, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Millendo Therapeutics, Filed by: New Enterprise Associates 15, L.P.
-
Beyond Identity Integration With Auth0 Enables Completely Passwordless Authentication
-
Beyond Identity Integration With Auth0 Enables Completely Passwordless Authentication
-
Strive Health Partners With NextGate to Support Whole-Patient Kidney Care
-
Axiado Secures Initial Closing of $20M Series B Investment
-
ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema
-
Sanofi (SNY) Acquires Tidal Therapeutics for $160M Upfront and Up to $310M in Milestones
-
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
-
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
-
Google-backed TAE Technologies raises $280 million from new, existing investors
-
CIT GAP Funds Invests in Floorwire to Give Commercial Owners Control of Architectural Data
-
Patreon Fuels the Future of the Creator Economy with $155 Million in Additional Funding
-
Creators' platform Patreon valued $4 billion in latest funding round
-
OmniSci Announces Multiple Opportunities To Accelerate Geospatial, GPU Database Knowledge At GTC 2021, April 12-16
-
Announcing Zero Trust Authentication for Managed Devices and BYOD
-
Announcing Zero Trust Authentication for Managed Devices and BYOD
-
ThreatQuotient Closes $22.5 Million in New Financing to Accelerate Innovation and Execution
-
Long Hill Capital Closes On $300M for Third Fund to Invest in Healthcare and Longevity Sectors in China
-
New Wave Foods® Launches Its Plant-Based Shrimp to Foodservice Companies throughout the U.S.
-
Form SC 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
-
CIT GAP Funds Invests in Linebird to Bring the Unmanned Systems Revolution to High Voltage Power Lines
-
Robinhood, at the heart of retail trading frenzy, files for own IPO
-
Study Shows New Relational Digital Therapeutic Significantly Reduced Problematic Substance Use During Pandemic
-
5th Stanford Drug Discovery Symposium (SDDS 2021) held virtually this year! April 19 - 20, 2021. Free registration!
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Oppenheimer & Co. Inc. Successfully Concludes 31st Annual Healthcare Conference
-
Lumos Pharma Inc. (NASDAQ: LUMO) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
-
CIT GAP Funds Invests in AtWork Systems to Support SMBs with Solutions for Streamlined Business Operations

